External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry
ConclusionCOMPASS-Eligible patients represent a substantial fraction of stable CAD/PAD patients encountered in routine clinical practice in the large international REACH registry suggesting good external applicability. COMPASS-Eligible patients experienced a higher rate of the primary outcome compared with COMPASS participants in the aspirin alone treatment arm.
Source: European Heart Journal - Category: Cardiology Source Type: research
More News: Aspirin | Bleeding | Cardiology | Cardiovascular | Heart | Heart Attack | Ischemic Stroke | Peripheral Vascular Disease (PVD) | Renal Failure | Stroke | Study